Date: 7 March 2016 | Topic: Inhaled Pharmaceuticals
Developing medicines that are delivered via the pulmonary and nasal routes for the treatment of local and systemic diseases is challenging. While the demonstration of safety, potency and purity is a fundamental part of the marketing authorization process for all drugs, incorporation of a delivery device greatly increases the complexity of the drug development process.
PPD® Laboratories GMP lab has been supporting the respiratory community across the product development continuum for more than 17 years. We have depth of experience evaluating drug/device combinations and have authored several publications and presentations on the topic. Our scientists have chosen a few of their presentations and publications to share with you.